Navigation Links
Micell Technologies Announces Presentation of Clinical Data at TCT 2011
Date:11/2/2011

alia and New Zealand. This trial completed enrollment in July 2011 with 183 patients enrolled.

About the MiStent DES

The MiStent Sirolimus Eluting Coronary Stent System is designed to optimize healing in patients with coronary artery disease. Micell's rapid-absorbing drug/polymer formulation is intended to precisely and consistently control drug elution and polymer exposure duration to reduce the safety risks associated with current commercially available drug-eluting stent technologies.

Using an approved drug (sirolimus) and polymer (PLGA), Micell's patented supercritical fluid technology allows a rigorously controlled drug/polymer coating to be applied to a bare-metal stent. The MiStent DES leverages the benefits of Eurocor's (CE Marked) Genius® MAGIC Cobalt Chromium Coronary Stent System, a state-of-the-art bare-metal stent, which has demonstrated excellent deliverability, conformability and flexibility. GLP pre-clinical trials have shown that the drug/polymer coating is eliminated from the MiStent DES within 45 to 60 days. In addition, the polymer-based coating is fully absorbed in tissue by 90 days in vivo, at which point the bare-metal stent remains. The MiStent DES is being evaluated in international clinical studies and patient enrollment is complete in those studies.

The MiStent Sirolimus Eluting Coronary Stent System is an investigational device. It is not yet approved or available for sale in any market.

About Micell Technologies Inc.

Micell Technologies® is a biomedical company that is enhancing the performance of medical devices with innovative drug-delivery systems. Its unique surface and polymer modification technologies enable Micell to precisely and consistently control drug elution and polymer exposure duration, creating the potential for a therapeutic solution to coronary artery disease without the long-term safety concerns associated with currently available drug-eluting ste
'/>"/>

SOURCE Micell Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStentâ„¢ Drug-Eluting Coronary Stent (DES)
2. Micell Technologies Announces Reduced Clinical Trial Sample Size for MiStent® Drug-Eluting Coronary Stent Based on Early Clinical Data
3. Micell Technologies Completes Enrollment in DESSOLVE II Study of the MiStent® Drug-Eluting Coronary Stent
4. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
5. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
6. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
7. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
8. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
9. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
10. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
11. Senesco Technologies Initiates Preclinical Studies for Cancer Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... DALLAS , September 17, 2014 ... Electronics Market by Component (Sensor, Battery, Memory Device, Display, ... and Fitness & Wellness), and by Geography - Global ... of medical electronics market is expected to reach $56.50 ... from 2014 to 2020. Browse 235 market ...
(Date:9/17/2014)... , Sept. 17, 2014  NuView Life Sciences, ... licensing and collaboration agreement with Otsuka Pharmaceutical Co., ... investigative genomic-based diagnostic biomarker to detect cancers of ... all other future diagnostic-imaging applications. NuView retains all ... delivery and in-vitro urine screen applications. ...
(Date:9/17/2014)... 17, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... earned a $4 million milestone payment from Achaogen, ... the initiation of a Phase 3 study of ... gram-negative bacterial infections.  The Phase 3 study is ... efficacy and safety of plazomicin compared to colistin ...
Breaking Medicine Technology:Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3
... 2011 Promax Applications Group ( www.promaxtpo.com ), ... and optimization solutions, today announced that Kimberly-Clark Corporation ... Trade Promotion Management (TPM) and Optimization (TPO) solution ... the world,s most recognized consumer brands sold in ...
... Va., March 1, 2011 Health Diagnostic Laboratory ... its partnership to develop a novel laboratory developed ... venture developing diagnostic test and surgical therapy solutions ... disease (CVD), coronary heart disease (CHD) and stroke ...
Cached Medicine Technology:Kimberly-Clark Corporation Selects Promax as its North America Trade Promotion Management and Optimization Solution Provider 2Health Diagnostic Laboratory, Inc. (HDL, Inc.) Partners With Gamma Therapeutics to Offer Breakthrough Diagnostic Assay for Heart Attack and Stroke Risk 2Health Diagnostic Laboratory, Inc. (HDL, Inc.) Partners With Gamma Therapeutics to Offer Breakthrough Diagnostic Assay for Heart Attack and Stroke Risk 3
(Date:9/17/2014)... Dr. Shalev is a Texas native, and grew up in ... University of Texas, and graduated with a Bachelors of Business ... lay in dentistry, and she went on to receive a ... Science Center at Houston School of Dentistry. Dr. Shalev practices ... Greater Houston Dental Society, and the Texas Dental Association. ...
(Date:9/17/2014)... ADVOCATE, the premier provider of radiology ... they have been awarded the exclusive billing agreement ... Indiana. , ADVOCATE will deliver a ... suite of billing process software functionality called Experience ... and data quality consistency by ensuring a timely, ...
(Date:9/17/2014)... Pittsburgh, PA (PRWEB) September 17, 2014 ... their exercise - even when they're already practicing or ... I was inspired to design a special fitness system ... or playing baseball or football," said an inventor from ... the MOBILITY FITNESS SYSTEM, which maximizes a body workout ...
(Date:9/17/2014)... announced today that will analyze how changes in ... contribute to healthy aging. , Conducted by ... a $10 million unrestricted gift from the Amway ... identify lifestyle and environmental factors that may help ... age. WELL will be designed, conducted, and analyzed ...
(Date:9/17/2014)... chromosomes could hold the key to a better understanding of ... according to new research from the University of Leeds. ... factor for melanoma. , It is well known that pigmentation ... at risk of developing melanoma. For example, paler people should ... easily. , It now appears that another risk factor is ...
Breaking Medicine News(10 mins):Health News:ADVOCATE Wins Radiology Billing Agreements with Fort Wayne Radiology 2Health News:ADVOCATE Wins Radiology Billing Agreements with Fort Wayne Radiology 3Health News:First-ever research study examines impacts of diet and lifestyle on healthy aging 2Health News:Chromosome buffers hold key to better melanoma understanding 2
... IVIG worked. Its ability to treat autoimmune diseases seemed ... immunoglobulin (IVIG) is a complex mixture of IgG antibodies ... from thousands of people, and is only FDA-approved to ... it off-label with varied success in patients with lupus, ...
... geographic convenience and the quality of services that can ... to an article// in the latest edition of the ... a developing trend towards urban centralisation of surgical services, ... care standards. ,However, this creates geographical distances ...
... The Public Works and Government Services Canada said that there ... programs this year.// ,The vaccine instead of being ... in the month of November. Dr. Sheela Basrur, Ontario's chief ... by the beginning of the flu season. Public Works buys ...
... a study conducted by Prof Bernard a senior lecturer at ... found that more number// of rural people of heart attacks ... ,Statistics show that heart disease mortality rates in rural areas ... in women than in urban areas. But the solution to ...
... Australians who have type 2 diabetes could also be at ... the latest issue of the Medical Journal of Australia.// ... Renal Impairment cO-existing with NIDDM (non-insulin dependent diabetes mellitus) - ... ever undertaken in Australian general practice. ,NEFRON examined ...
... A study in Britain has found that nearly one-third of ... purpose, due to rupture, or simply slipping off// during sex, ... ,NOP world undertook a survey of nearly 497 people for ... nearly 64% were groping in the dark about the reasons ...
Cached Medicine News:Health News:Single Sugar Enables Antibody to Treat Inflammation 2Health News:Single Sugar Enables Antibody to Treat Inflammation 3Health News:Bolster Rural Surgical Services 2
The CGIL iridectomy contact glass was designed by Riquin, Fankhauser et al. to perform full thickness peripheral laser iridectomies....
The CGVL vitrectomy contact glass was designed by Rol, Fankhauser et al. for photodisruptive YAG laser procedures in the posterior vitreous....
For newly born children 10 mm internal diameter of the cornea part. Designed to work with argon/YAG Lasers....
... The HAAG-STREIT OM 900 Ophthalmometer uses ... the three requirements of Helmholtz: 1. The ... of the distance between the Ophthalmometer and ... are independent of the distance between the ...
Medicine Products: